Yarrow Bioscience, Inc.
PublicYarrow Bioscience, Inc. is now publicly traded
The data on this page reflects Yarrow Bioscience, Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series A
Dec 18, 2025
Total Funding Raised
$300M
Company Overview
Yarrow Bioscience, Inc. is a biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, including Graves' disease and thyroid eye disease.
AI Layer
Non-AI
Keywords
Yarrow Bioscience, Inc. Comparables
Compare Yarrow Bioscience, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AV7 Limited | 90% | |
| Ollin Biosciences | 80% | |
| Regeneron Pharmaceuticals | 80% |
Yarrow Bioscience, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 18, 2025 | ||||
| Series A | Dec 17, 2025 |
Yarrow Bioscience, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series A |
| LifeSci Venture Partners | Series A |
| Perceptive Advisors | Series A |
| OrbiMed | Series A |
| Logos Capital | Series A |
| venBio | Series A |
| RTW Investments | Series A |
Recent news
Latest coverage and updates
- has_revenueSep 13, 2026
Yarrow Bioscience, Inc. has revenue of $100K.
- receives_financingSep 11, 2026
Yarrow Bioscience, Inc. received financing of $150M in underwritten public offering on Sep 11th '26.
- receives_financingJul 29, 2026
Yarrow Bioscience, Inc. received financing of $5.9M in Series A on Jul 29th '26.
Yarrow Bioscience, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access